BCAB BIOATLA INC

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights.

Conference Call and Webcast Information

Date: Thursday, November 13, 2025

Time: 4:30 p.m. ET

Webcast Link: 

Dial-in Numbers: (800)-343-4136 (domestic), (203) 518-9843 (international)

Conference ID: BIOATLA

The press release with the financial results will be accessible prior to the conference call through “” in the News & Events section of the company’s website. A replay of the call will also be available through “” in the Investors section of the company’s website.

About BioAtla®, Inc.

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. To learn more about BioAtla, Inc., visit .

Internal Contact: 

Richard Waldron 

Chief Financial Officer 

BioAtla, Inc. 



858.356.8945 

External Contact: 

Joyce Allaire

LifeSci Advisors, LLC 



EN
05/11/2025

Underlying

BCABBIOATLA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOATLA INC

 PRESS RELEASE
Free
BCAB BIOATLA INC

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Re...

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half ...

7h / 18m 1 EN
 PRESS RELEASE
Free
BCAB BIOATLA INC

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrat...

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas — Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment SAN DIEGO, Nov. 07...

November 7, 2025 1 EN
 PRESS RELEASE
Free
BCAB BIOATLA INC

BioAtla to Announce Third Quarter 2025 Financial Results and Provide B...

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights. Conference C...

November 5, 2025 1 EN
 PRESS RELEASE
Free
BCAB BIOATLA INC

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 w...

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced presentation of a poster entitled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase RO...

October 23, 2025 1 EN
 PRESS RELEASE
Free
BCAB BIOATLA INC

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA...

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025 Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for >6 months​Maximally tolerated dose not yet defined; dose escalation continues; currently testing 1.8 mg dose level​ SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE...

October 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch